CA2819894A1 - Composes antiviraux - Google Patents
Composes antiviraux Download PDFInfo
- Publication number
- CA2819894A1 CA2819894A1 CA2819894A CA2819894A CA2819894A1 CA 2819894 A1 CA2819894 A1 CA 2819894A1 CA 2819894 A CA2819894 A CA 2819894A CA 2819894 A CA2819894 A CA 2819894A CA 2819894 A1 CA2819894 A1 CA 2819894A1
- Authority
- CA
- Canada
- Prior art keywords
- optionally substituted
- independently
- occurrence
- heterocycle
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42390610P | 2010-12-16 | 2010-12-16 | |
| US61/423,906 | 2010-12-16 | ||
| PCT/US2011/065501 WO2012083170A1 (fr) | 2010-12-16 | 2011-12-16 | Composés antiviraux |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2819894A1 true CA2819894A1 (fr) | 2012-06-21 |
Family
ID=45464913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2819894A Abandoned CA2819894A1 (fr) | 2010-12-16 | 2011-12-16 | Composes antiviraux |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2651885A1 (fr) |
| JP (1) | JP5906253B2 (fr) |
| CN (1) | CN103354808B (fr) |
| CA (1) | CA2819894A1 (fr) |
| MX (1) | MX2013006951A (fr) |
| WO (1) | WO2012083170A1 (fr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2367824B1 (fr) | 2008-12-23 | 2016-03-23 | AbbVie Inc. | Dérivés de pyrimidine antiviraux |
| CN102245604A (zh) | 2008-12-23 | 2011-11-16 | 雅培制药有限公司 | 抗病毒化合物 |
| MX2011010905A (es) | 2009-04-15 | 2011-11-01 | Abbott Lab | Compuestos antivirales. |
| NZ600608A (en) | 2009-12-18 | 2015-01-30 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
| EP2651923A4 (fr) * | 2010-12-15 | 2014-06-18 | Abbvie Inc | Composés anti-viraux |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| JP2016527232A (ja) | 2013-07-17 | 2016-09-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ |
| WO2015038596A1 (fr) | 2013-09-11 | 2015-03-19 | Emory University | Compositions à base de nucléotide et de nucléoside et utilisations correspondantes |
| CN104610332B (zh) * | 2015-02-26 | 2019-11-08 | 成都安斯利生物医药有限公司 | 一种制备四氢呋喃-3-三氟硼酸钾的方法 |
| CN104672261A (zh) * | 2015-02-27 | 2015-06-03 | 成都安斯利生物医药有限公司 | 一种制备四氢呋喃-3-硼酸频呐醇酯的方法 |
| CN104592278A (zh) * | 2015-02-28 | 2015-05-06 | 成都安斯利生物医药有限公司 | 一种制备四氢吡喃-3-硼酸频呐醇酯的方法 |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2017023631A1 (fr) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Inhibiteurs du virus de l'hépatite c |
| TW202321249A (zh) | 2015-08-26 | 2023-06-01 | 比利時商健生藥品公司 | 使用作為ｐｒｍｔ５抑制劑之新穎經６－６雙環芳香環取代之核苷類似物 |
| EA201892031A1 (ru) | 2016-03-10 | 2019-02-28 | Янссен Фармацевтика Нв | Замещенные аналоги нуклеозидов для применения в качестве ингибиторов prmt5 |
| HUE057460T2 (hu) | 2016-03-22 | 2022-05-28 | Merck Sharp & Dohme | Nikotinos acetilkolin receptorok alloszterikus modulátorai |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| PE20190706A1 (es) | 2016-10-03 | 2019-05-17 | Janssen Pharmaceutica Nv | Analogos novedosos de carbanucleosidos sustituidos de sistema anular monociclico y bicicilo para su uso como inhibidores de prmt5 |
| EA201992026A1 (ru) | 2017-02-27 | 2020-01-24 | Янссен Фармацевтика Нв | Применение биомаркеров при идентификации пациентов, имеющих рак, которые будут характеризоваться наличием восприимчивости к лечению ингибитором prmt5 |
| JP7312171B2 (ja) | 2017-11-24 | 2023-07-20 | ヤンセン ファーマシューティカ エヌ．ベー． | ピラゾロピリジノン化合物 |
| WO2019110734A1 (fr) | 2017-12-08 | 2019-06-13 | Janssen Pharmaceutica Nv | Nouveaux analogues spirobicycliques |
| TW202112375A (zh) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | 使用ｐｒｍｔ５抑制劑治療癌症之方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| RS20050741A (en) * | 2003-04-02 | 2007-06-04 | Boehringer Ingelheim International Gmbh., | Pharmaceutical compositions for hepatitis c viral protease inhibitors |
| ES2710662T3 (es) * | 2005-06-24 | 2019-04-26 | Biotron Ltd | Compuestos de acilguanidina con actividad antiviral |
| MX2008012053A (es) * | 2006-03-21 | 2008-12-17 | Joyant Pharmaceuticals Inc | Promotores de apoptosis de molecula pequeña. |
| ES2392104T3 (es) | 2006-06-16 | 2012-12-04 | Syngenta Participations Ag | Derivados de carboxamida etenílica útiles como microbiocidas |
| CA2745119A1 (fr) * | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibiteurs du virus de l'hepatite c de type ns5a |
| EP2393359A4 (fr) * | 2009-02-09 | 2012-10-03 | Enanta Pharm Inc | Dérivés du dibenzimidazole liés |
| WO2010096462A1 (fr) * | 2009-02-17 | 2010-08-26 | Enanta Pharmaceuticals, Inc | Dérivés du diimidazole lié |
| MX2011008982A (es) * | 2009-02-27 | 2011-09-15 | Enata Pharmaceuticals Inc | Inhibidores del virus de la hepatitis c. |
| US8796466B2 (en) * | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI476190B (zh) * | 2009-03-30 | 2015-03-11 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
| TW201038559A (en) * | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| EP2337781B1 (fr) | 2009-06-11 | 2014-07-23 | AbbVie Bahamas Ltd. | Composés antiviraux pour le traitement d'infections hcv |
| WO2010148006A1 (fr) * | 2009-06-16 | 2010-12-23 | Enanta Pharmaceuticals, Inc. | Inhibiteurs du virus de l'hépatite c |
| CA2791630A1 (fr) * | 2010-03-04 | 2011-09-09 | Enanta Pharmaceuticals, Inc. | Agents pharmaceutiques combinatoires au titre d'inhibiteurs de la replication du vhc |
-
2011
- 2011-12-16 JP JP2013544826A patent/JP5906253B2/ja active Active
- 2011-12-16 CA CA2819894A patent/CA2819894A1/fr not_active Abandoned
- 2011-12-16 WO PCT/US2011/065501 patent/WO2012083170A1/fr active Application Filing
- 2011-12-16 CN CN201180066574.3A patent/CN103354808B/zh active Active
- 2011-12-16 MX MX2013006951A patent/MX2013006951A/es not_active Application Discontinuation
- 2011-12-16 EP EP11806100.1A patent/EP2651885A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012083170A1 (fr) | 2012-06-21 |
| EP2651885A1 (fr) | 2013-10-23 |
| CN103354808B (zh) | 2016-08-10 |
| JP2014504296A (ja) | 2014-02-20 |
| CN103354808A (zh) | 2013-10-16 |
| JP5906253B2 (ja) | 2016-04-20 |
| MX2013006951A (es) | 2013-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9394279B2 (en) | Anti-viral compounds | |
| CA2819894A1 (fr) | Composes antiviraux | |
| CA2807847C (fr) | Composes antiviraux | |
| EP2367824B1 (fr) | Dérivés de pyrimidine antiviraux | |
| US8921514B2 (en) | Anti-viral compounds | |
| US20120115918A1 (en) | Anti-Viral Compounds | |
| CA2758484A1 (fr) | Composes antiviraux | |
| JP6790202B2 (ja) | 抗ウィルス化合物 | |
| AU2016238925B2 (en) | Anti-viral compounds | |
| AU2014203655B2 (en) | Anti-viral compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |
Effective date: 20171218 |